|Research your Stock | Technical Calls | Live Market Action | Archives | Join Xchange|
Welcome to Market Insights.
In this edition, we have Aarthastra Consulting recommending Kwality for an upside of around 54% while Rudra Shares and Stock Brokers recommending Syngene for an upside of 24%. In other fundamental recommendations, HDFC Sec are recommending Atul Auto at CMP and Firstcall India Equity are recommending Alembic Pharma for the mid- to long-term. Lastly, we have Mr. Varun Parekh giving essential guidance for those you have just started trading. Also, given that the TeamLease Services IPO is currently underway, we are offering our readers an opportunity to read recommendations on this IPO by various analysts and research-houses.
We have also been encouraging our readers to visit Finbridge Expo, an event that brings financial advisors and investors on one platform, where the former can exhibit their services while the later can avail those services. Realising that Finbridge Expo is an ideal event for financial advisors as well as investors, we are giving our readers an opportunity to register for this event. Registration for this event is totally FREE, and readers can click here to register for the event. More details about the event are available here.
We also have a technical query answered by our experts on board.
If you like us, please rate us on Facebook.
|Buy this pharma scrip for an upside of 24%|
|According to Rudra Shares and Stock Brokers, considering the extensive future expansion plans, positive cash in the books, and strong clientele with unique business, we have estimated the share price of the company as per P/E valuation, putting 32x on FY17E EPS of 15.01. We recommend investors to BUY this pharma scrip.
|Buy this auto scrip at CMP and add on dips to Rs. 439-455 band|
|According to HDFC Sec, after achieving critical 7.5% domestic market share with diesel 3-wheeler SCVs (small CVs), Atul Auto is launching a gasoline (petrol) vehicle. Incubated in-house under the tutelage of an industry veteran, the new product will open up vital metro/NCR and export markets.
|This low debt pharma company is expected to perform well in the coming quarters; Buy|
|According to Firstcall India Equity, the company with its low debt and high growth in international generics and domestic formulation business is expected to perform well in the coming quarters. Thus we recommend investors to BUY this scrip with a target price of Rs.730.00 for the medium and long term.
|Have you just begun trading? Then you NEED to read this|
|According to Mr. Varun Parekh, becoming a trader might be a wise decision, but it is subject to conditions. While a trader has infinite chance to multiply its capital on a daily basis, the chances of loosing capital are same as infinite. Until and unless you follow some rules, I hardly doubt you can make money.
|TeamLease Services IPO
|Ask an Expert - An answer to your question is just an e-mail away!|
|IndiaNotes.com's Ask an Expert section has been very popular among our audience and readers, particularly because of our experts on board like Mr. Rakesh Rathod and Mr. Rakesh Sethi among others for the prompt and convincing solutions they offer.
Readers are most welcome to post their questions to our experts on board and get their queries answered.
|Advertise with us | Write for us | Blog on Xchange | Archives | Feedback|